Non-platinum gemcitabine combinations in non-small cell lung cancer

Lung Cancer

Volumn 38, Issue 2 SUPPL., 2002, Pages 51-54

  Marx, Gavin ^a   Harper, Peter ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Combination chemotherapy; Docetaxel; Elderly; Gemcitabine; Irinotecan; Non small cell lung cancer; Paclitaxel; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; HEMATOLOGIC DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036844837     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0169-5002(02)00358-6     Document Type: Conference Paper

References (18)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
2. Anderson H., et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 83:2000;447-453.
3. ten Bokkel Huinink W.W., et al. Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer. 26:1999;85-94.
4. Vansteenkiste J.F., et al. Clinical-benefit response in advanced non-small cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol. 12:2001;1221-1230.
5. Perng R.P., Chen Y.M., Ming-Liu J., et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J Clin Oncol. 15:1997;2097-2102.
6. Krajnik G., et al. Vinorelbine-gemcitabine in advanced non-small cell lung cancer (NSCLC): An AASLC phase II trial. Austrian Association for the Study of Lung Cancer. Ann Oncol. 11:2000;993-998.
7. Chen Y.M., et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. Chest. 117:2000;1583-1589.
8. Laack E., et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: A phase II trial. Eur J Cancer. 37:2001;583-590.
9. Lorusso V., et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J Clin Oncol. 18:2000;405-411.
10. Palmeri S., et al. Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): A multicentre phase II clinical trial. Lung Cancer. 34:2001;115-123.
11. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
12. Gridelli C., Perrone F., Cigolari S., et al. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) Phase 3 Trial: gemcitabine+vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients. Proc Am Soc Clin Oncol. 20:2001;1230a.
13. Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol. 18:2000;2529-2536.
14. Georgoulias V., Kouroussis C., Androulakis N., et al. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. J Clin Oncol. 17:1999;914-920.
15. Rubio G., Blajman C., Capó A., et al. Docetaxel and gemcitabine in metastatic non-small cell lung cancer (NSCLC). A phase II study. Preliminary feasibility report. Proc Am Soc Clin Oncol. 18:1999;2012a.
16. Hejna M., Kornek G.V., Raderer M., et al. Treatment of patients with advanced non small cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer. 89:2000;516-522.
17. Rebattu P., Quantin X., Morere J.F. A phase II study of docetaxel (D) and gemcitabine (G) combination in patients (Pts) with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 19:2000;2124a.
18. Georgoulias V., et al. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: Early results of a randomized trial. Lung Cancer. 34:(Suppl 4):2001;47-51.